180 Life Sciences

180 Life Sciences Corp. is a clinical-stage biotechnology company based in Menlo Park, California, dedicated to developing novel therapeutics to address unmet medical needs in inflammatory diseases, fibrosis, and chronic pain. The company is advancing several drug candidates through Phase IIb/III clinical trials, utilizing distinct platforms such as the Fibrosis and Anti-TNF platform, which targets fibrosis and tumor necrosis factors; the Synthetic Cannabidiol (CBD) Analogs platform, which consists of man-made derivatives of CBD; and the α7nAChR platform, focusing on the alpha 7 nicotinic acetylcholine receptor. By leveraging expertise from renowned institutions like Oxford University, the Hebrew University, and Stanford University, 180 Life Sciences aims to provide innovative solutions in the field of therapeutics.